

## Supplementary Material

### Membrane properties of cultured red blood cells derived from human induced pluripotent stem cells

**Running head:** Membrane properties of iPSC-derived cultured RBCs

Claudia Bernecker <sup>1</sup>, Eva M. Matzhold <sup>1</sup>, Dagmar Kolb <sup>2,3</sup>, Afrim Avdili <sup>1</sup>, Lisa Rohrhofer <sup>1</sup>, Annika Lampl <sup>1</sup>, Martin Trötz Müller <sup>4</sup>, Heike Singer <sup>5</sup>, Johannes Oldenburg <sup>5</sup>, Peter Schlenke <sup>1</sup> and Isabel Dorn <sup>1\*</sup>

## Supplementary Tables

**Table S1:** Human iPSC lines used in the study

| iPSC   | name      | origin                 | reprogramming                                  | reference |
|--------|-----------|------------------------|--|-----------|
| iPSC-1 | PEB-iPSC  | erythroblasts          | Lentiviral<br>(OCT4, SOX2, KLF4, C-MYC)        | [1]       |
| iPSC-2 | CD34-iPSC | cord blood CD34+ cells | Lentiviral<br>(OCT4, SOX2, KLF4, C-MYC)        | [2]       |
| iPSC-3 | PEB-AL    | erythroblasts          | Episomal<br>(OCT3/4, SOX2, KLF4, LIN28, L-MYC) |           |
| iPSC-4 | CM1       | erythroblasts          | Episomal<br>(OCT4, SOX2, LIN28, KLF4, L-MYC)   | [3]       |
| iPSC-5 | SANi-003A | erythroblasts          | Episomal<br>(OCT4, SOX2, LIN28, C-MYC)         | [4]       |

**Table S2:** Reagents (all from BioRad) used for RBC antigen expression analyses

| Antigen                                 | ID-card                                 | Antibodies                                  |
|---|---|---|
| cRBC suspension in Diluent 2 (LISS)     |   |   |
| ABO, D                                  | DiaClon ABO/Rh for patients, monoclonal |   |
| CcEe K                                  | DiaClon Rh-Subgroups + K monoclonal     |   |
| C <sup>w</sup>                          | DiaClon anti-C <sup>w</sup> monoclonal  |   |
| Fy <sup>a</sup>                         | ID-Card Fy <sup>a</sup>                 | ID-Anti-Fy <sup>a</sup> (human), Id-n 09210 |
| Fy <sup>b</sup>                         | ID-Card Fy <sup>b</sup>                 | ID-Anti-Fy <sup>b</sup> (human), Id-n 09310 |
| M                                       | DiaClon anti-M monoclonal               |   |
| N                                       | DiaClon anti-N monoclonal               |   |
| S                                       | LISS/Coombs                             | Anti-S (human), Id-n 19010                  |
| s                                       | LISS/Coombs                             | Anti-s (human), Id-n 19110                  |
| cRBC suspension in Diluent 1 (Bromelin) |   |   |
| k                                       | Anti-k (human)                          |   |
| Kp <sup>a</sup>                         | Anti-Kp <sup>a</sup> polyclonal         |   |
| Kp <sup>b</sup>                         | Anti-Kp <sup>b</sup> polyclonal         |   |
| Jk <sup>a</sup>                         | DiaClon Anti-Jk <sup>a</sup> monoclonal |   |
| Jk <sup>b</sup>                         | DiaClon Anti-Jk <sup>b</sup> monoclonal |   |

**Table S3:** Cellular characteristics of cRBC\_iPSCs compared to cRBC\_adult, CB-derived nRETs, and PB-derived nRBCs. Generation of cRBC\_adult from adult HSPCs and subsequent phenotyping was performed by our group as published [5]. All methods were identical to methods used for cRBC\_iPSCs culturing. Cell diameter was measured microscopically. Mean corpuscular volume MCV [fl], mean corpuscular hemoglobin content (CHm) [pg] and mean corpuscular hemoglobin concentration (CHCm) [g/dl] were assessed by ADVIA analyzer [5]. Due to limited cell numbers ADVIA analyses were not performed with cRBC\_iPSCs. The Hb composition was determined by HPLC analysis as published [1, 2]. (n.d. not determined; FC flow cytometry analysis)

|  | cRBC_iPSC        | cRBC_adult       | CB-derived nRET  | PB-derived nRBC  |
|--|------------------|------------------|------------------|------------------|
| <b>Phenotype flow cytometry (% positive cells)</b> [data derived from 5] |                  |                  |                  |                  |
| GPA  | >99              | >99              | >99              | >99              |
| Band3  | >99              | >99              | >99              | >99              |
| CD36   | 21.5 ± 12.3      | 23.2 ± 5.4       | 31.6 ± 9.4       | 4.7 ± 1.7        |
| CD49d  | 2.9 ± 2.1        | 11.3 ± 5.4       | 6 ± 1.6          | n.d.             |
| CD71   | 94.4 ± 3.3       | 80 ± 5.3         | 95 ± 3           | 1.2 ± 0.4        |
| Thiazol orange   | 33.6 ± 16        | 41.8 ± 1.1       | 88 ± 4.2         | 2.6 ± 0.6        |
| <b>Cell size, volume, Hb content</b>                                     |                  |                  |                  |                  |
| Diameter (µm)  | 11.2 ± 1.5       | 9.4 ± 0.2        | 8.1 ± 2.2        | 7.4 ± 0.8        |
| MFI FSC (FC)   | 359,434 ± 23,355 | 340,900 ± 70,740 | 334,606 ± 18,539 | 294,483 ± 8,531  |
| MFI SSC (FC)   | 339,976 ± 16,074 | 269,605 ± 47,145 | 324,167 ± 37,941 | 300,242 ± 16,997 |
| MCV (fl) [5]   | n.d.             | 128.7 ± 11.7     | 125.1 ± 5.7      | 89.3 ± 1.5       |
| CHm (pg) [5]   | n.d.             | 32.7 ± 1.3       | 35.2 ± 1         | 30.8 ± 1.5       |
| CHCm (g/dL) [5]  | n.d.             | 26.0 ± 2.2       | 28.3 ± 1.1       | 34.7 ± 1.5       |
| Hemoglobin (mg/mL)<br>(Drabkin staining)                                 | 205.6 ± 46.0     | 136.3 ± 24.7     | 201.4 ± 29.7     | 131.3 ± 17.9     |
| % Hemoglobin (HPLC)<br>[data derived from 1,2]                           | HbF 68.5 ± 2.7   | HbF 9.1 ± 4.3    | HbF 87.3 ± 1.1   | HbF 3.3 ± 2.2    |
|  | HbA 3.3 ± 1.1    | HbA 76.2 ± 7.8   | HbA 14.7 ± 5.1   | HbA 87.4 ± 2.5   |
|  | embHb 18.5 ± 1.8 | embHb <1         | embHb <1         | embHb <1         |
| <b>Deformability and osmotic resistance (OR)</b>                         |                  |                  |                  |                  |
| LORRCA Elmax   | 0.44 ± 0.01      | 0.49 ± 0.01 [5]  | 0.53 ± 0.02      | 0.6 ± 0.01       |
| Osmotoc resistance<br>(% NaCl resulting in<br>50% hemolysis)             | 0.3              | 0.35 – 0.3 [5]   | 0.35 – 0.3       | 0.45 – 0.4       |

## **Supplementary Figure legends**

**Figure S1: Flow cytometry characterization of day 18 cRBC\_iPSCs.** Bars represent mean  $\pm$  SD (n=18).

**Figure S2: Maturation stage of cRBC\_iPSCs determined by microscopy.** Representative cytopsin preparations obtained from nRBCs, nRETs, and cRBCs derived from the different iPSC lines, and stained with New methylene blue for the residual nucleic acid. (Scale bar 20  $\mu$ m, magnification of 100 $\times$  with oil).

**Figure S3: Maturation stage of cRBC\_iPSCs determined by flow cytometry.** Representative flow cytometry analyses for Thiazole orange and CD71 obtained from nRBCs, nRET, and cRBCs derived from the different iPSC lines.

**Figure S4: Representative microscopic images obtained from cell diameter measurements.** Upper part: May-Gruenwald stained cytopsin preparations (40fold magnification, scale bars represent 25  $\mu$ m). Lower part: Magnification of marked section from the upper part. Cell diameters (white bars) were calculated using the EVOS M5000 software. At least 300 cells per slide were evaluated.


**Figure S5: Mean immunofluorescence intensity (MFI) for Ankyrin,  $\alpha$ -Spectrin, Band 3, and f-Actin.** The MFI was calculated over the whole image field and quantified with the Nikon General Analysis 3 Software. No statistical differences were observed between cells from the different sources (n = 4 each).

**Figure S6: Expression of blood group antigens by cRBC\_iPSCs 1 (phenotyping).** Expression of ABO, Rhesus, Kell, Kidd, Duffy, and MNSs antigens were evaluated using commercial accessible test systems for diagnostic in gel cards. The cRBC\_iPSCs shown here are O Rh (D)


pos, ccD.Ee, Cw-, Kell-k+, Kpa-Kpb+, Jka+Jkb-, Fya-Fyb-, M+N+, S+s+. Controls (ctl) are negative.

**Figure S7: Expression of blood group antigens by cRBC\_iPSCs 5 (phenotyping).** Expression of ABO, Rhesus, Kell, Kidd, Duffy, and MNSs antigens were evaluated using commercial accessible test systems for visual evaluation in gel cards. The cRBC\_iPSCs shown here are O Rh (D) pos, CcD.ee, Cw-, Kell-k+, Kpa-Kpb+, Jka+Jkb+, Fya+Fyb-,M+N-, S-s+. Controls (ctl) are negative.


### Supplementary Figures




**Figure S1:** Flow cytometry characterization of day 18 cRBC\_iPSCs.




**Figure S2:** Maturation stage of cRBC\_iPSCs determined by microscopy.



**Figure S3:** Maturation stage of cRBC\_iPSCs determined by flow cytometry.




**Figure S4:** Representative microscopic images obtained from cell diameter measurements.




**Figure S5:** Mean immunofluorescence intensity (MFI) for Ankyrin,  $\alpha$ -Spectrin, Band 3, and f-Actin.





**Figure S6:** Expression of blood group antigens by cRBC\_iPSCs 1 (phenotyping).



**Figure S7:** Expression of blood group antigens by cRBC\_iPSCs 5 (phenotyping).

## Supplementary References

1. Bernecker, C.; Ackermann, M.; Lachmann, N.; Rohrhofer, L.; Zaehres, H.; Arauzo-Bravo, M.J.; van den Akker, E.; Schlenke, P.; Dorn, I. Enhanced ex vivo generation of erythroid cells from human induced pluripotent stem cells in a simplified cell culture system with low cytokine support. *Stem cells and development* **2019**, *28*, 1540-1551, doi:10.1089/scd.2019.0132.
2. Dorn, I.; Klich, K.; Arauzo-Bravo, M.J.; Radstaak, M.; Santourlidis, S.; Ghanjati, F.; Radke, T.F.; Psathaki, O.E.; Hargus, G.; Kramer, J., *et al.* Erythroid differentiation of human induced pluripotent stem cells is independent of donor cell type of origin. *Haematologica* **2015**, *100*, 32-41, doi:10.3324/haematol.2014.108068.
3. Jamil, M.A.; Singer, H.; Al-Rifai, R.; Nüsgen, N.; Rath, M.; Strauss, S.; Andreou, I.; Oldenburg, J.; El-Maarri, O. Molecular analysis of fetal and adult primary human liver sinusoidal endothelial cells: A comparison to other endothelial cells. *International journal of molecular sciences* **2020**, *21*, 7776
4. Varga, E.; Hansen, M.; Wust, T.; von Lindern, M.; van den Akker, E. Generation of human erythroblast-derived ipsc line using episomal reprogramming system. *Stem Cell Res* **2017**, *25*, 30-33, doi:10.1016/j.scr.2017.10.001.
5. Bernecker, C.; Kofeler, H.; Pabst, G.; Trotschmuller, M.; Kolb, D.; Strohmayer, K.; Trajanoski, S.; Holzapfel, G.A.; Schlenke, P.; Dorn, I. Cholesterol deficiency causes impaired osmotic stability of cultured red blood cells. *Frontiers in physiology* **2019**, *10*, 1529, doi:10.3389/fphys.2019.01529.